Table 2 Pre-randomisation vitamin D levels for the season when sample was taken and association with specific melanoma disease characteristics
Pre-randomisation vitamin D levels in nmol/L | ||
|---|---|---|
N | Median [interquartile range] | |
All patients | 341 | 56.5 [38.6–76.5] |
Timing of sample (season) | ||
January–March | 96 | 47.1 [30.0–69.0] |
April–June | 77 | 54.3 [36.3–75.3] |
July–September | 77 | 73.3 [57.5–90.7] |
October–December | 91 | 52.2 [38.0–68.3] |
Primary melanoma Breslow thickness at diagnosis in mm | ||
≤2 | 103 | 54.5 [36.2–72.6] |
>2-4 | 107 | 56.9 [39.1–82.3] |
>4 | 111 | 56.9 [43.1–75.7] |
Unknown | 20 | 56.3 [38.9–82.4] |
Primary melanoma ulceration | ||
Present | 137 | 54.9 [41.0–76.7] |
Absent | 151 | 60.1 [36.9–77.2] |
Unknown | 53 | 53.3 [39.1–71.2] |
Disease stage at trial entry | ||
II | 90 | 55.6 [42.3–76.6] |
III | 251 | 56.6 [37.7–76.5] |
Time from initial melanoma diagnosis to randomisation in years | ||
<1 | 233 | 56.5 [40.0–76.6] |
1–2 | 40 | 54.3 [36.3–75.9] |
>2 | 68 | 57.2 [37.4–71.6] |
Trial arm | ||
Bevacizumab | 171 | 52.6 [37.5–76.7] |
Observation | 170 | 59.8 [39.8–76.5] |
